The mammalian protein DEK has been implicated in multiple cellular processes, including transcriptional regulation, mRNA processing, and chromatin remodeling, and is associated with a number of clinical autoimmune and neoplastic conditions. The connection between DEK and cancer exists at multiple levels: (a) the t(6;9) chromosomal translocation that characterizes a subtype of acute myelogenous leukemia cases results in the formation of a DEK-CAN fusion oncoprotein; (b) a fragment of dek cDNA is capable of partially reversing the radiation-sensitive phenotype of fibroblasts cultured from ataxia-telangiectasia patients; and (c) increased levels of dek mRNA have been found to be associated with hepatocellular carcinoma, glioblastoma, and melanoma. Despite the growing list of cancer subtypes with a connection to DEK, the factors that mediate its expression have yet to be characterized. Here we undertake the analysis of DEK regulation by mapping the discrete elements within the proximal promoter that are responsible for constitutive transcription of dek in transformed cells. We find that functional elements include an inverted CCAAT box and a YY1 consensus binding site, and the introduction of point mutations into these sites markedly diminishes transcriptional activity. In addition, we identify the transcriptional activator NF-Y as a member of the CCAAT-binding complex, and verify binding of the transcription factor YY1 at its consensus site in the dek promoter. The discovery of NF-Y and YY1 as regulatory determinants of DEK expression is consistent with the well-documented roles of these two factors in cellular proliferation and transformation.
Introduction
DEK is a 43 kDa mammalian nuclear phosphoprotein that has been linked to several human diseases. DEK was first identified as part of a fusion protein originating from the t(6;9) chromosomal translocation that characterizes a subtype of acute myelogenous leukemia (AML) (von Lindern et al., 1992) . The oncoprotein DEK -CAN merges the upstream regulatory region and N-terminal nine-tenths of DEK with the C-terminal two-thirds of the much larger CAN nucleoporin. This localizes CAN to the nucleoplasm rather than the nuclear membrane (Fornerod et al., 1995) . In addition, DEK has been shown to be an autoantigen in a number of autoimmune disorders; the presence of anti-DEK antibodies correlates strongly with the development of pauci-articular juvenile rheumatoid arthritis (JRA), and even more specifically with cases involving ocular symptoms (Arnaudo et al., 1998; Dong et al., 2000; Murray et al., 1997; Sierakowska et al., 1993) . DEK has also been linked to ataxia-telangiectasia, as a fragment of dek cDNA reverses the mutagen-sensitive phenotype that characterizes fibroblasts from patients with this disease (Meyn et al., 1993) . Finally, independent differential display studies have revealed an increased expression of dek in three neoplastic conditions: hepatocellular carcinoma, glioblastoma, and melanoma (Kondoh et al., 1999; Kroes et al., 2000; Grottke et al., 2000) .
In spite of these clinical correlations, the predominant biological function of DEK remains unclear. DEK does not belong to any characterized family of proteins, and its only recognizable sequence motifs are a putative SAP DNA-binding domain and two stretches of acidic residues (Aravind and Koonin, 2000) . Our group has identified DEK as the factor constitutively bound to the phorbol ester-inducible peri-ets site within the human immunodeficiency virus type-2 long terminal repeat in monocytic and lymphoid cells (Fu et al., 1997; Faulkner et al., 2001) . In addition we have demonstrated that DEK can bind preferentially to specific alleles of the class II HLA -DQA1 promoter. As this haplotype is associated with autoimmune disease, and particularly with JRA, this finding may connect DEK function with a clinical phenotype (Adams et al., submitted) . Other groups have implicated DEK in chromatin remodeling and mRNA processing, and identified it as a member of a complex of proteins that plays a part in the nonsense-mediated decay pathway (Alexiadis et al., 2000; McGarvey et al., 2000; Le Hir et al., 2000 .
Little is known about the factors that control DEK expression. DEK protein is present at high levels in many tissue types and immortalized mammalian cell lines (von Lindern et al., 1992) . The identification of increased levels of dek mRNA in different types of cancer compared with matched non-neoplastic tissue suggests that there is regulation that is responsive to cell growth or division. Others have reported that the 520 bp immediately upstream of the transcriptional start site contained strong promoter activity as measured by chloramphenicol acetyltransferase assay, but no analysis of the functional elements within this promoter, which also regulates DEK -CAN expression, has previously been published (von Lindern et al., 1992) . In this report, we map the discrete elements responsible for this activity, and find that binding sites for the transcription factors Nuclear Factor-Y (NF-Y) and Yin Yang-1 (YY1), as well as several novel regulatory sequences, mediate transcriptional activation in different transformed cell lines. We show that mutation of only two bases in the YY1 binding site results in markedly diminished transcriptional activity in vivo. It is notable that both YY1 and NF-Y are associated with the processes of cellular proliferation and transformation. Thus, the involvement of these two transcription factors in DEK promoter regulation is consistent with published reports of increased dek expression in various tumors.
Results
The dek promoter contains multiple discrete elements responsible for transcriptional activity
The nucleotide sequence for the dek promoter is available in the GenBank database under GenBank Accession Number AL031774. Figure 1a depicts the organization of the dek gene. The region approximately 500 base pairs upstream through 500 base pairs downstream of the transcriptional start site corresponds to a CpG island, which is consistent with the high level of DEK expression seen in many cell types. We have subcloned reporter constructs in which the promoter sequence has been positioned upstream of firefly luciferase; elements within the promoter were analysed through the creation of a series of nested deletions with truncation at the 5' end. We chose to begin the analysis in two cell types: the Jurkat T-cell lymphoma line and the T98G glioblastoma line. The former was chosen because functional studies of DEK as a transcription factor were done in these cells; the latter was chosen to represent an example of a tumor subtype known to be associated with increased expression of DEK compared with its tissue of origin. Figure 1b ,c demonstrate that there are no significant functional elements between 7496 and 7355 in either cell type, as removal of these bases does not alter transcriptional activity. As seen in Figure 2 , the activity Figure 1 The 355 base-pair region immediately upstream of the dek transcriptional start site contains a strong promoter. (a), the structure of the DEK gene is depicted. Since the numbering after +1 corresponds to the mRNA, the remaining 500 base pairs of the 1 kb CpG island (which is genomic DNA) is condensed after that point. Reporter plasmids were constructed by positioning the indicated promoter fragments upstream of the coding sequence for firefly luciferase in pGL3. (b,c) , cells are transiently co-transfected with pGL3 reporter constructs and pRL-SV40, in which the viral promoter drives transcription of renilla luciferase. Activity is normalized for transfection efficiency by taking the ratio of firefly to renilla luciferase measurements. Values are shown as the per cent of activity compared with the 7496 construct; data shown are the mean+s.d. for two (T98G) or three (Jurkat) independent transfections and representative of 45 experiments conferred by the 500 base pairs proximal to the transcriptional start site is over 100 times that of promoter-less transcription (+1) in both cell types.
Analysis of serial 5' deletions of the DEK promoter is presented in Figure 2 . Comparing Figure 2a ,b reveals that there are several elements common to both cell types, and others that appear to be tissue-specific. Using the TRANSFAC database, we compared these elements to consensus binding motifs for vertebrate transcription factors (Heinemeyer et al., 1998) . Although loss of the 11 base pairs between 7355 and 7344 reduces transcriptional activity by half in both Jurkat and T98G cells, the sequence does not resemble any currently identified sites for DNA-binding proteins. This is also true for the T98G-specific regions located between 7205 and 7196, and between 7185 and 7177. These sequences are shown in Figure 3 . Figure 3 also shows the sequence between 7167 and 7151, the loss of which results in a moderate increase in transcriptional activity in Jurkat cells. This region contains an element that resembles the site for the lymphoid transcription factor Ikaros-2; however mutation of the bases necessary for Ikaros-2 binding does not reproduce the gain of activity seen with the deletion (data not shown). Between 7177 and 7167 there is an inverted CCAAT box, and deletion of this region results in a loss of activity in Jurkat and T98G cells. In both cell types the most significant loss of activity occurs between 7151 and 7122; since the values are already low in the T98G cells compared with 7496, the apparent drop is dampened by the scale of the graph. This region contains a 100% match to the consensus binding site for the transcription factor YY1.
The inverted CCAAT box located 170 bp upstream of the transcriptional start site confers activity and binds the NF-Y protein
In order to determine if loss of the CCAAT box itself is responsible for the reduction in activity that occurs between 7177 and 7167, the mutation depicted in Figure 4a was introduced into the 7177 construct. In both cell types, alteration of three base pairs critical to the CCAAT motif reproduces the 50% reduction in activity seen with the loss of the 10 bases (Figure 4b ,c). There are a variety of transcription factors that bind to CCAAT boxes, including members of the CCAAT/ Enhancer Binding Protein family, CCAAT Displacement Protein, and NF-Y, which is also known as CBF or CP1 (Mantovani, 1999) . However, these factors have crucial binding requirements outside of the pentanucleotide itself (Mantovani, 1999) . It has been shown that the optimal consensus NF-Y binding site Figure 2 for the experimental data. The first three elements bear no similarity to currently catalogued consensus binding motifs for known transcription factors. The fourth element is similar to the binding site for the T-cell transcription factor Ikaros-2, but the site-specific mutational analysis does not support a role for Ikaros-2 in the regulation of DEK transcription. Bracketed numerals indicate the position number of the first and last written base extends beyond the CCAAT nucleotides in both directions; inspection of the CCAAT box from the DEK promoter ( Figure 5a ) reveals matching bases at seven out of eight of these additional positions (Mantovani, 1998) . Thus, we predicted that the complex of proteins bound to this site would include NF-Y. Electrophoretic mobility shift assay was used to visualize the proteins from Jurkat and T98G nuclear extracts that bind to the CCAAT box region from the DEK promoter (Figure 5b ). Band 2 is specifically dependent on the CCAAT element in both cell types: competition with unlabeled probe eliminates binding, while unlabeled oligonucleotides that harbor the same mutation used in the reporter gene assays in Figure 4 do not affect the band. With T98G nuclear extract, the band appears to be a doublet. This finding is consistent with published observations of alternative splicing of NF-YA, one of the three subunits of the NF-Y transcription factor trimer. In particular, there are two NF-YA isoforms that differ by 28 amino acids, and NF-Y trimers containing either form are capable of DNA binding and transcriptional activation (Li et al., 1992) . A slight difference in their migration in shift assays has already been noted by others (Li et al., 1992) . In addition, the ratio of the two isoforms has been found to differ significantly in different tissue types, and has specifically been shown to vary between lymphoid and non-lymphoid cells, as seen here (Li et al., 1992) . T98G extract contains a second binding activity (Figure 5b , band 3) that is not specific to the CCAAT box, as the mutant DNA eliminates as much binding as the unlabeled probe. In order to see whether NF-Y is present in the specific complex, anti-NF-YA antibody was preincubated with nuclear extract prior to the addition of labeled DNA probe. Indeed, lanes 5 and 14 exhibit a supershift of the specific complex (band 1). This band is not due to antibody binding directly to probe (lane 2), and does not appear when polyclonal goat antibody to an unrelated protein (vimentin) is added to nuclear extract (lanes 4 and 13). The anti-NF-YA antibody used in our assay has been shown by others to detect both alternatively spliced isoforms of the protein (Duan et al., 2001) . Moreover, this antibody apparently does not crossreact with any other cellular proteins (Duan et al., 2001) . Its specificity is especially relevant to this supershift, since as mentioned previously, the CCAAT motif is known to bind other transcription factors.
YY1 binds to a transcriptionally active element at 7135
To evaluate whether the dramatic reduction in activity occurring between 7151 and 7122 results from the loss of a YY1 consensus binding site, the mutation depicted in Figure 6a was introduced into the 7151 construct. In both cell types, alteration of two bases within the binding site reproduced the loss of transcriptional activity seen with the truncation (Figure  6b,c) . Note that the 100% value for 7496 (not shown) is omitted in Figure 6c , in order to make the scale reasonable for displaying the low activities of the relevant constructs. Although the loss of activity seen with mutation or deletion of the YY1 consensus site is large when considered as a fold drop from 7151, the overall activity of this truncation is already so low compared with the full-length promoter that it is difficult to assess the true contribution of this site to DEK transcription. Therefore, we introduced the same mutation in the context of the 7496 construct. Figure  6d ,e show that the alteration of just two base pairs Figure 1 ; data shown represent the average of two independent transfections significantly reduces the activity from the entire halfkilobase region. Thus, the YY1 site contributes substantially to the regulation of dek expression.
Electrophoretic mobility shift assay with Jurkat nuclear extract confirmed binding of YY1 to this element (Figure 7) . Bands 2 and 4 are specific to the consensus site itself, as competition with the mutant depicted in Figure 7a (and used in Figure 6 ) does not diminish its intensity; conversely band 3 binds at some other location common to both wild-type and mutant oligonucleotide sequences (compare lanes 5 -7 with 8 -10). The addition of two different polyclonal antibodies to YY1 results in a supershift of bands 2 and 4 (lanes 4 and 12), whereas the addition of polyclonal rabbit antibody to a different transcription factor (Sp1) does not create a supershift (lane 3). Neither anti-YY1 antibody shifts the probe in the absence of nuclear extract (data not shown).
As bands 2 and 4 from Figure 7b both bind with sequence specificity and are supershifted by anti-YY1 antibodies, we sought to verify that YY1 is a member of both of these complexes of proteins. To this end, we spiked Jurkat nuclear extract with bacterially expressed and purified recombinant YY1 protein (Figure 7c ). Lane 6 shows that purified YY1 protein alone runs at the same mobility as band 4 from nuclear extract. Lane 2 shows Jurkat nuclear extract alone, and lanes 3 and 4 show competition with the competitors depicted in Figure 7a , in order to again verify the specificity of bands 2 and 4, and the lack of specificity of band 3. Lane 4, in which 200 ng of purified YY1 has been added to nuclear extract, clearly shows an augmentation of band 4 in comparison to lane 2; this is consistent with the observation that purified YY1 alone exhibits the same mobility as band 4. In addition, band 2 is also augmented in lane 5 compared to lane 2, suggesting that the complex of proteins that comprises band 2 contains YY1. This augmentation of band 2 can be seen even more clearly in lane 1, in which 600 ng of YY1 protein has been added to nuclear extract. Thus, YY1 is indeed a member of both complexes of nuclear proteins that bind specifically at 7135. As mutation of this element at only two base pairs eliminates up to 85% of transcriptional activity from the entire 500-base pair promoter (Figures 6d,e) , YY1 clearly plays a pivotal role in DEK regulation.
Discussion
In this report, we map the discrete cis-acting elements responsible for the transcriptional activity of the dek promoter. Specific protein binding sites were identified by the introduction of point mutations within these elements. Finally, the transcription factors NF-Y and YY1 were proven to bind to active elements at 7170 and 7135, respectively. This represents the first characterization of the upstream elements important to dek and dek-can gene expression.
The dek promoter contains no consensus TATA box. Although CCAAT boxes characterize many promoters from higher eukaryotes, there is an enhanced correlation between the CCAAT element (especially in its inverted form as seen in this case) and TATA-less promoters (Mantovani 1998 (Mantovani , 1999 . In addition, it has been shown that CCAAT boxes that bind NF-Y are invariably flanked by at least one other functionally important promoter element (Mantovani, 1999) . This is also seen in the dek promoter, as there are neighboring contributory elements in both cell types (Figure 2) .
The presence of NF-Y binding at a positively contributing element within the dek promoter is congruent with the observations of increased levels of dek in multiple tumors, as NF-Y has been connected with cellular proliferation and cancer. It has recently been shown that expression of a dominant negative NF-YA subunit, which inhibits the DNA-binding of endogenous wild-type NF-Y, results in retardation of fibroblast cell growth (Hu and Maity, 2000) . In particular, it was found that the number of cells entering S phase was decreased, and that induction of S phase following serum stimulation of quiescent cells (Figure 4 ). Double-stranded probe (a, 'probe') was end-labeled and incubated in the presence of 700 ng poly-dIdC DNA with Jurkat (b), (lanes 3 -11) or T98G (lanes 12 -20) nuclear extract prior to electrophoresis. Competition with 20 -100 ng of unlabeled double-stranded probe (self; lanes 6 -8 and 15 -17), or with DNA of the sequence labeled 'mutant' in a (mut; lanes 9 -11 and 18 -20), shows that band 2 (which is a doublet in T98G extract) binds specifically to the CCAAT box, while band 3 does not. For lanes 4 -5 and 13 -14, 3 mg of goat polyclonal antibody to NF-Y (N) or vimentin (V) were preincubated with protein before the addition of probe, resulting in the supershifted band 1 only when anti-NF-Y is added. Lane 1 demonstrates that the free probe alone does not remain at the mobility of these bands, and lane 2 shows that the anti-NF-Y alone does not shift the probe was delayed. The dominant negative mutant also decreased expression of several cancer-related genes, supporting a mechanism in which NF-Y regulates proliferation through the modulation of factors involved in the cell cycle and growth response (Hu and Maity, 2000) . In addition, it has been reported that three unrelated anti-cancer drugs inhibit the binding of NF-Y to the CCAAT box (reviewed in Mantovani, 1999) . These agents include the synthetic HMN-154, the marine alkaloid ET743, and the soy phytoestrogen Genistein Minuzzo et al., 2000; Zhou and Lee, 1998) . It is currently unclear whether the anti-proliferative effects of these drugs are related to inhibition of NF-Y; however, that possibility is consistent with the phenotype of the dominant negative mutant discussed above. Taken together, these observations suggest that NF-Y, shown in our report to bind to an upstream activating element in the dek promoter, may be in part responsible for the increased expression of dek seen in neoplasia.
The zinc-finger protein YY1 has been shown to regulate cellular and viral gene expression by three independent mechanisms: activation, repression, and initiation of transcription (reviewed in Shi et al., 1997; Shrivastava and Calame, 1994) . The significant activity remaining in construct 7496my (see Figure 6d ,e), as well as the upstream position of the YY1 binding site, make it unlikely that YY1 acts as a transcriptional initiator at the dek promoter. Mutation of two bases within the site abolishes YY1 binding as well as severely reducing the activity from the whole and truncated promoters; together these two facts argue against a role for YY1 as a transcriptional repressor of dek. Thus it seems likely that YY1 activates DEK transcription, which is of interest when one considers the well documented role of YY1 in cellular proliferation. Studies in NIH3T3 cells have revealed that quiescent cells express little or no YY1, while stimulation of cell division with whole serum or insulin-like growth factor-1 results in increased YY1 expression (Flanagan, 1995) . In addition, the phenotype of YY1-deficient mice suggests an involvement in cell division: knock-out results in embryonic lethality shortly after implantation, a developmental stage that coincides with rapid proliferation (Donohoe et al., 1999) . The demise of YY1 7/7 embryos prior to the formation of the primitive streak suggests a proliferative defect resulting in failure to reach a threshold number of epiblast cells (Donohoe et al., 1999) . Furthermore, it has recently been discovered that the Figure 6 In both Jurkat and T98G cells, mutation of the YY1 binding site duplicates the drop in activity seen between positions 7151 and 7122, and dramatically reduces the activity of the 7496 promoter construct. (a), position numbers correspond to the bases indicated by arrows. (wt) indicates the wild-type sequence present in the dek promoter, while (my) depicts the introduced mutation in underlined italics; the YY1 consensus binding sequence is also shown (N indicates any base). In (b -e), 7151my contains the mutation shown in (a) in the context of 7151, whereas 7496my contains the same mutation but in the context of the full-length promoter. Note that in order to provide an appropriate scale, the horizontal axis in (c) is from 0 to 6%, and the 100% value for 7496 is not shown; however, the values are still percentages of the activity from that construct. Data were collected and normalized as in Figure 1 ; data shown represent the average of two independent transfections retinoblastoma tumor-suppressor protein interacts with YY1 in a cell-cycle-dependent manner, with the complex existing in growth-arrested cells but absent in S phase; this interaction destabilizes the association of YY1 with DNA (Petkova et al., 2001) . It was shown that in smooth muscle cells, overexpression of YY1 activated DNA synthesis while concomitant overexpression of retinoblastoma blocked the effect, revealing a tightly regulated model in which elevation of free nuclear YY1 favors progression into S phase (Petkova et al., 2001) . Finally, the currently identified targets of YY1 regulation by transcriptional activation include the oncogene c-myc, while many YY1-repressible genes are associated with differentiation (Shrivastava and Calame, 1994) . Thus, the possible addition of dek to the list of YY1-activated genes is very consistent with reports showing increased expression of DEK in tumors from various tissues of origin.
As the t(6;9) translocation fuses the 5' end of the dek gene with the 3' end of can, the proximal promoter analysed in this report is also responsible for the regulation of the DEK -CAN oncoprotein in the leukemic cells that characterize AML. Although the mechanism of action of DEK -CAN remains unknown, the consistent presence of the fusion transcript in t(6;9) cells suggests a causative role in leukemogenesis (Fornerod et al., 1995) . To this end, it will be of interest to test whether anti-cancer agents affecting the transcription factors that control expression from this promoter, such as the NF-Y modulators Genistein, ET743, and HMN-154, have particular therapeutic potential for t(6;9) AML by down-regulating the DEK -CAN oncoprotein itself.
It is becoming increasingly clear that like many proteins, DEK functions in multiple cellular processes, including chromatin organization, gene regulation, and mRNA processing. The importance of DEK to mammalian biology is evident from the varied clinical conditions that have been associated with DEK. An understanding of the factors that control its expression will contribute to the elucidation of DEK's role in the normal cell and in malignancy.
Materials and methods

Construction of dek promoter constructs
The following primers were designed for PCR amplification of the 500 base pairs immediately proximal to the transcriptional start site of dek: 5'-GCGGCCCGGGACTG-CTCATCATCT, 3'-TGGCACGCGAGGGCACGAGGAG-GTTCT. Segments were amplified using the GC rich PCR system (Roche) and genomic human DNA prepared from neutrophils. Products were cloned into the pGEM-T Easy vector (Promega) and excised with NcoI and SacI for subcloning into the pGL3-Basic firefly luciferase-encoding vector (Promega). Alternate 5' primers were used to generate nested deletions. For the constructs 7177mc and 7151my, point mutations were introduced within the 5' amplification primers; their sequences are indicated in the figures. The 7496my mutant was constructed by utilizing the naturally occurring BsaMI site at 7160 to exchange a fragment of the 7496 promoter for a PCR product in which the YY1 mutation was introduced within the 5' amplification primer. The identity of all constructs has been verified by automated sequencing (University of Michigan Core Facilities).
Cell culture
T98G glioblastoma cells were obtained from ATCC and passaged in Dulbecco's modified Eagle's medium (BioWhittaker) with 10% fetal bovine serum and antibiotics. Jurkat T cells were obtained from ATCC and passaged in RPMI 1640 (Bio-Whittaker) with 10% fetal bovine serum and antibiotics. Transient transfection of Jurkat T cells 10 6 cells were incubated in an electroporation cuvette with 0.4 ml serum-free media, 5 mg dek promoter reporter DNA in pGL3, and 0.05 mg renilla luciferase reporter driven by the SV-40 promoter (pRL-SV40, Promega). Cells were pulsed at 350 V with an Electroporator II (Invitrogen) set to 1000 microfarad, and diluted in 10 ml media with serum for 24 h before quantification of luciferase activity.
Transient transfection of T98G glioblastoma cells
Cells were grown to 80% confluency in six-well plates and washed in serum-free media. Five mg dek promoter reporter DNA and 0.05 mg pRL-SV40 were incubated with 20 ml Lipofectamine 2000 (Invitrogen) in 1 ml serum-free media for 30 min. DNA-liposome complexes were added to cells for 5 h and rinsed away with serum-free media. After a 24 h incubation in media with serum, cells were lysed and assayed for reporter activity.
Measurement of luciferase activity
Cell lysates were assayed for reporter activity using the Dual Luciferase Assay system (Promega). Cells were washed three times, lysed according to the manufacturer's instructions, and centrifuged at 14 000 g for 5 min to clear away cell debris. 10 ml of lysate was analysed by sequential addition of 75 ml of firefly and renilla luciferase substrates using a TD-20/20 autoinjecting luminometer (Turner Designs).
Preparation of oligonucleotide probes
Oligonucleotides were purchased from Invitrogen. Singlestranded oligonucleotides were end-labeled with 32 P-g-ATP (Amersham) using T4 polynucleotide kinase (Promega), and annealed by heating and cooling slowly in 0.5 M NaCl. Double-stranded probe was purified over a G-50 sephadex column, and diluted to 10 000 counts/ml.
Electrophoretic mobility shift assay
Each binding reaction contained 20 000 counts of probe and T98G or Jurkat nuclear extract (prepared using the method of Dignam et al. (1983) or purchased from Geneka Biotechnology), or a mixture of Jurkat nuclear extract and bacterially expressed and purified YY1 protein (Austral Biologicals). These were incubated for half an hour with unlabeled competitors in buffer containing 700 ng poly-dIdC as a non-specific DNA competitor, 100 mM KCl, 10 mM Tris, 5 mM Dithiothreitol, 1 mM EDTA, 0.1 mg/ml Bovine serum albumin and 4% glycerol. Reactions were run out on a TrisGlycine-EDTA non-denaturing gel for 2 h at 125 volts. Gels were dried and exposed to film overnight. Binding reactions and electrophoresis were carried out at room temperature for the CCAAT box site and at 48C for the YY1 site. Supershifting was performed by preincubation of antibody and protein for 15 min prior to addition of probe. The following antibodies were utilized at the specified amounts: 3 mg goat anti-CBF-B (sc-7712 X, Santa Cruz), 3 mg goat anti-vimentin (Sigma), 4 mg rabbit anti-YY1 (sc-281 X, Santa Cruz), 2 ml rabbit anti-YY1 (Geneka) or 2 ml rabbit anti-Sp1 (Geneka).
